Clinical Trial Update: Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Thymosin α1 to reduce acute pneumonia in bulky non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Thymosin α-1 (thymosin alpha-1)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED